HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshihiro Nanki Selected Research

Retinoids

1/2015Could retinoids be a potential treatment for rheumatic diseases?
2/2013Am80, a retinoic acid receptor agonist, ameliorates murine vasculitis through the suppression of neutrophil migration and activation.
6/2010The effect of synthetic retinoid, Am80, on T helper cell development and antibody production in murine collagen-induced arthritis.
10/2009Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshihiro Nanki Research Topics

Disease

51Rheumatoid Arthritis
08/2022 - 11/2002
14Arthritis (Polyarthritis)
11/2021 - 01/2005
8Inflammation (Inflammations)
01/2019 - 10/2005
8Experimental Arthritis
05/2015 - 12/2004
6Vasculitis (Vasculitides)
08/2022 - 02/2013
6Autoimmune Diseases (Autoimmune Disease)
11/2021 - 05/2009
6Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
01/2020 - 04/2011
6Infections
12/2014 - 07/2011
5Interstitial Lung Diseases (Interstitial Lung Disease)
05/2021 - 06/2002
4Glomerulonephritis
08/2022 - 12/2010
4Atherosclerosis
11/2021 - 06/2005
4Rheumatic Diseases (Rheumatism)
11/2020 - 01/2015
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
06/2019 - 05/2002
3Osteoarthritis
12/2017 - 11/2002
3Neoplasms (Cancer)
09/2016 - 06/2005
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
01/2022 - 04/2020
2COVID-19
12/2021 - 09/2020
2Dermatomyositis (Dermatopolymyositis)
11/2020 - 03/2012
2Lupus Nephritis
06/2019 - 01/2015
2Nephritis
10/2018 - 12/2010
2Myositis (Idiopathic Inflammatory Myopathies)
01/2015 - 03/2012
2Lung Diseases (Lung Disease)
11/2012 - 11/2012
2Opportunistic Infections (Opportunistic Infection)
11/2012 - 11/2012
2Experimental Nervous System Autoimmune Disease
10/2009 - 11/2005
1Liver Failure
01/2022
1Disease Progression
01/2022
1Adult-Onset Still's Disease
01/2022
1Acute Liver Failure (Fulminant Hepatic Failure)
01/2022
1Cytokine Release Syndrome
12/2021

Drug/Important Bio-Agent (IBA)

10Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2021 - 10/2005
10CytokinesIBA
12/2021 - 11/2002
9Methotrexate (Mexate)FDA LinkGeneric
01/2022 - 04/2011
9Chemokine CX3CL1IBA
07/2021 - 12/2004
8Biological ProductsIBA
08/2022 - 11/2012
8Abatacept (Orencia)FDA Link
08/2022 - 09/2016
8GlucocorticoidsIBA
12/2021 - 07/2014
8Prednisolone (Predate)FDA LinkGeneric
07/2021 - 06/2002
8ChemokinesIBA
05/2021 - 01/2005
7Antirheumatic Agents (DMARD)IBA
08/2022 - 07/2011
7Tumor Necrosis Factor InhibitorsIBA
01/2018 - 01/2009
6Etanercept (Enbrel)FDA Link
09/2016 - 12/2010
5tocilizumab (atlizumab)FDA Link
12/2021 - 11/2012
5Monoclonal AntibodiesIBA
07/2021 - 10/2005
5LigandsIBA
05/2021 - 11/2002
4Tacrolimus (Prograf)FDA LinkGeneric
12/2021 - 08/2011
4AntibodiesIBA
11/2021 - 09/2009
4Pharmaceutical PreparationsIBA
01/2021 - 11/2012
4RetinoidsIBA
01/2015 - 10/2009
4tamibaroteneIBA
01/2015 - 10/2009
3Infliximab (Remicade)FDA Link
12/2021 - 11/2012
3AutoantibodiesIBA
11/2021 - 01/2009
3quetmolimabIBA
07/2021 - 01/2018
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2019 - 01/2008
3Lysophosphatidic Acid ReceptorsIBA
01/2019 - 08/2013
3lysophosphatidic acidIBA
01/2019 - 08/2013
3Adalimumab (Humira)FDA Link
09/2016 - 11/2013
3Interleukin-6 (Interleukin 6)IBA
01/2016 - 10/2014
3Messenger RNA (mRNA)IBA
10/2014 - 05/2002
3Therapeutic UsesIBA
08/2014 - 01/2005
2Peroxidase (Myeloperoxidase)IBA
08/2022 - 07/2019
2Intravenous Immunoglobulins (IVIG)FDA Link
01/2022 - 07/2014
2Adrenal Cortex Hormones (Corticosteroids)IBA
01/2022 - 05/2014
2tofacitinibIBA
12/2021 - 01/2021
2Janus Kinase InhibitorsIBA
12/2021 - 01/2018
2InterleukinsIBA
12/2021 - 06/2010
2Cyclosporine (Ciclosporin)FDA LinkGeneric
12/2021 - 10/2018
2Biomarkers (Surrogate Marker)IBA
11/2021 - 05/2015
2Immunoglobulin G (IgG)IBA
01/2021 - 08/2014
2Trimethoprim (Proloprim)FDA LinkGeneric
01/2020 - 01/2017
2Thymidine Monophosphate (TMP)IBA
01/2020 - 01/2017
2SulfamethoxazoleFDA LinkGeneric
01/2020 - 01/2017
2LipidsIBA
01/2019 - 08/2013
2AdipokinesIBA
12/2017 - 09/2016
2ResistinIBA
12/2017 - 09/2016
2C-Reactive ProteinIBA
05/2015 - 06/2013
2EnzymesIBA
10/2014 - 06/2002
2Collagen Type II (Type II Collagen)IBA
08/2014 - 08/2013
2Rituximab (Mabthera)FDA Link
07/2014 - 04/2009
2Anti-Bacterial Agents (Antibiotics)IBA
05/2014 - 01/2008
2Interleukin-17 (Interleukin 17)IBA
06/2010 - 10/2009
2Interferon-gamma (Interferon, gamma)IBA
10/2009 - 10/2005
2Myosins (Myosin)IBA
10/2009 - 11/2005
2NF-kappa B (NF-kB)IBA
01/2007 - 01/2005
1Certolizumab PegolFDA Link
07/2022
1SteroidsIBA
01/2022
1Immunosuppressive Agents (Immunosuppressants)IBA
01/2022
1ColchicineFDA LinkGeneric
12/2021
1Chloroquine (Aralen)FDA LinkGeneric
12/2021
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
12/2021
1canakinumabFDA Link
12/2021
1sarilumabIBA
12/2021
1Hydroxychloroquine (Plaquenil)FDA LinkGeneric
12/2021
1baricitinibIBA
12/2021
1apremilastIBA
12/2021
1siltuximabIBA
12/2021

Therapy/Procedure

21Therapeutics
07/2021 - 06/2002
3Biological Therapy
01/2022 - 11/2012
2Intraperitoneal Injections
04/2017 - 02/2013
1Critical Care (Surgical Intensive Care)
01/2022
1Liver Transplantation
01/2022